These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27842887)

  • 81. Analysis of polar metabolites by hydrophilic interaction chromatography--MS/MS.
    Jian W; Xu Y; Edom RW; Weng N
    Bioanalysis; 2011 Apr; 3(8):899-912. PubMed ID: 21510763
    [TBL] [Abstract][Full Text] [Related]  

  • 82. MS-based metabolomics facilitates the discovery of in vivo functional small molecules with a diversity of biological contexts.
    Yan L; Nie W; Parker T; Upton Z; Lu H
    Future Med Chem; 2013 Oct; 5(16):1953-65. PubMed ID: 24175746
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Metabolomics: moving to the clinic.
    Nordström A; Lewensohn R
    J Neuroimmune Pharmacol; 2010 Mar; 5(1):4-17. PubMed ID: 19399626
    [TBL] [Abstract][Full Text] [Related]  

  • 84. An untargeted metabolomics-driven approach based on LC-TOF/MS and LC-MS/MS for the screening of xenobiotics and metabolites of Zhi-Zi-Da-Huang decoction in rat plasma.
    Wu H; Li X; Yan X; An L; Luo K; Shao M; Jiang Y; Xie R; Feng F
    J Pharm Biomed Anal; 2015 Nov; 115():315-22. PubMed ID: 26275719
    [TBL] [Abstract][Full Text] [Related]  

  • 85. An introduction to MS imaging in drug discovery and development.
    Lodén H; Shariatgorji M; Nilsson A; Andrén PE
    Bioanalysis; 2015; 7(20):2621-7. PubMed ID: 26511071
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A case of personalized and precision medicine: Pharmacometabolomic applications to rare cancer, microbiological investigation, and therapy.
    Cristoni S; Bernardi LR; Malvandi AM; Larini M; Longhi E; Sortino F; Conti M; Pantano N; Puccio G
    Rapid Commun Mass Spectrom; 2021 Jan; 35(2):e8976. PubMed ID: 33053249
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Advances in mass spectrometry applied to pharmaceutical metabolomics.
    Drexler DM; Reily MD; Shipkova PA
    Anal Bioanal Chem; 2011 Mar; 399(8):2645-53. PubMed ID: 21107980
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The growing landscape of metabolomics and lipidomics: applications to medicinal chemistry and drug discovery.
    Palacios G; Bowling JJ; Abdolvahabi A
    Future Med Chem; 2019 Mar; 11(6):495-498. PubMed ID: 30888878
    [No Abstract]   [Full Text] [Related]  

  • 89. Clinical metabolomics: a pivotal tool for companion diagnostic development and precision medicine.
    Tolstikov V; Akmaev VR; Sarangarajan R; Narain NR; Kiebish MA
    Expert Rev Mol Diagn; 2017 May; 17(5):411-413. PubMed ID: 28317395
    [No Abstract]   [Full Text] [Related]  

  • 90. Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation.
    van der Hooft JJ; Padmanabhan S; Burgess KE; Barrett MP
    Metabolomics; 2016; 12():125. PubMed ID: 27471437
    [TBL] [Abstract][Full Text] [Related]  

  • 91. MS/MS networking guided analysis of molecule and gene cluster families.
    Nguyen DD; Wu CH; Moree WJ; Lamsa A; Medema MH; Zhao X; Gavilan RG; Aparicio M; Atencio L; Jackson C; Ballesteros J; Sanchez J; Watrous JD; Phelan VV; van de Wiel C; Kersten RD; Mehnaz S; De Mot R; Shank EA; Charusanti P; Nagarajan H; Duggan BM; Moore BS; Bandeira N; Palsson BØ; Pogliano K; Gutiérrez M; Dorrestein PC
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):E2611-20. PubMed ID: 23798442
    [TBL] [Abstract][Full Text] [Related]  

  • 92. MetCirc: navigating mass spectral similarity in high-resolution MS/MS metabolomics data.
    Naake T; Gaquerel E
    Bioinformatics; 2017 Aug; 33(15):2419-2420. PubMed ID: 28402393
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Improving MetFrag with statistical learning of fragment annotations.
    Ruttkies C; Neumann S; Posch S
    BMC Bioinformatics; 2019 Jul; 20(1):376. PubMed ID: 31277571
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Molecular networking in infectious disease models.
    Harris MB; Lesani M; Liu Z; McCall LI
    Methods Enzymol; 2022; 663():341-375. PubMed ID: 35168796
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Editorial: (Pharmaco)Metabolomics in Drug Discovery and Individualisation of Treatment.
    Katsila T; Patrinos GP
    Curr Pharm Des; 2017; 23(14):2027. PubMed ID: 28701139
    [No Abstract]   [Full Text] [Related]  

  • 96. Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine.
    Kohler I; Hankemeier T; van der Graaf PH; Knibbe CAJ; van Hasselt JGC
    Eur J Pharm Sci; 2017 Nov; 109S():S15-S21. PubMed ID: 28502671
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Metabolomic Approach in Probing Drug Candidates.
    Liu C; Alessandro A; Xia Y
    Curr Top Med Chem; 2017; 17(15):1741-1749. PubMed ID: 27848895
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Network topological indices, drug metabolism, and distribution.
    González-Díaz H
    Curr Drug Metab; 2010 May; 11(4):283-4. PubMed ID: 20545616
    [No Abstract]   [Full Text] [Related]  

  • 99. Reaction Tracking and High-Throughput Screening of Active Compounds in Combinatorial Chemistry by Tandem Mass Spectrometry Molecular Networking.
    Chung HH; Kao CY; Wang TA; Chu J; Pei J; Hsu CC
    Anal Chem; 2021 Feb; 93(4):2456-2463. PubMed ID: 33416326
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [On the molecular drug design from viewpoint of precision medicine].
    Guo ZR
    Yao Xue Xue Bao; 2017 Jan; 52(1):71-9. PubMed ID: 29911773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.